Previous 10 | Next 10 |
home / stock / mmed:cc / mmed:cc news
Psychedelics are all the rage these days thanks to a major surge in psychedelic research and media reporting on hallucinogens. This research has revealed that various psychedelics may have significant mental health benefits, making the substances prime candidates as alternatives for often u...
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Thursday, August ...
2023-07-26 08:45:24 ET Palm Beach, FL – July 26, 2023 – FinancialNewsMedia.com News Commentary – Psychedelic and hallucinogenic medicines market have been growing consistently over the past several years and are expected to continue to rise in the coming yea...
Over the past couple of years, a class of illegal drugs has captured the mainstream public’s attention by the throat and refused to let go. Psychedelics have joined the wave of drug reform that has swept across America in the past two decades and left dozens of states with legal recrea...
The Massachusetts for Mental Health Options (MMHO) committee recently kicked off efforts to add a psychedelics legalization measure on next year’s ballot. The recently formed committee has filed paperwork to put a measure that would legalize therapeutic psychedelic use in front of voters...
A recent report from The Wall Street Journal has revealed that billionaire and Twitter CEO Elon Musk uses ketamine to alleviate depression. Ketamine started as a dissociative anesthetic in the 1970s before people discovered that it also reduced depressive symptoms and... Read more »...
The Food and Drug Administration recently released a draft guidance on research protocols for psychedelic substances. This move signals the probable use of these drugs as treatments for mood disorders such as post-traumatic stress disorder and depression. In a statement, Dr. Tiffany Farchione...
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management tea...
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), today announced that, based upon a preliminary vote assessment, shareholders have elected all six of the Company’s nominees – CEO Robert Barrow, Dr. Suzanne Bruhn, Dr....
Psilocybin is one of several psychedelics that have exhibited therapeutic potential against various common mental disorders. Research has revealed that psilocybin (magic mushrooms) can deliver long-term benefits against mental disorders such as depression, anxiety, and substance-abuse disorders...
News, Short Squeeze, Breakout and More Instantly...
Hallucinogenic persistent perception disorder (HPPD) is an intoxication disorder caused by psychedelic drugs that encompasses a range of visual disturbances that occur in different time frames. The disorder also causes extreme anxiety as well as out-of-body sensations and is marked by shame as w...
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the...
All Common shares will remain listed on Nasdaq Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today ...